Value of monitoring Nrf2 activity for the detection of chemical and oxidative stress

Biochemical Society Transactions

Volumn 43, Issue , 2015, Pages 657-662

  Mutter, Fiona E ^a   Park, B Kevin ^a   Copple, Ian M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antioxidant response element; Hazard assessment; Kelch like ECH associated protein 1 (Keap1); Nuclear factor erythroid 2 related factor 2 (Nrf2); Stress response; Toxicity

Indexed keywords

TRANSCRIPTION FACTOR NRF2; MACROMOLECULE; NFE2L2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT RESPONSIVE ELEMENT; ARTICLE; CELL DEDIFFERENTIATION; CELL STRESS; CELL VIABILITY; CHEMICAL STRESS; DRUG DISPOSITION; HAZARD ASSESSMENT; HEPATOMA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LIVER CELL; MONITORING; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN SENSITIZATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; MACROMOLECULE; METABOLISM; TOXICITY;

MAMMALIA;

GENE EXPRESSION REGULATION; HUMANS; MACROMOLECULAR SUBSTANCES; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84938769241     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20150044     Document Type: Article

References (49)

1. Finkel, T. (2011) Signal transduction by reactive oxygen species. J. Cell Biol. 194, 7-15 CrossRef PubMed
2. Bryan, H.K., Olayanju, A., Goldring, C.E. and Park, B.K. (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem. Pharmacol. 85, 705-717 CrossRef PubMed
3. Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A. and Hayes, J.D. (2013) Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32, 3765-3781 CrossRef PubMed
4. Hayes, J.D., McMahon, M., Chowdhry, S. and Dinkova-Kostova, A.T. (2010) Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. Antioxid. Redox Signal. 13, 1713-1748 CrossRef PubMed
5. Ma, Q. (2013) Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53, 401-426 CrossRef PubMed
6. Copple, I.M., Goldring, C.E., Kitteringham, N.R. and Park, B.K. (2008) The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology 246, 24-33 CrossRef PubMed
7. Shelton, L.M., Park, B.K. and Copple, I.M. (2013) Role of Nrf2 in protection against acute kidney injury. Kidney Int. 84, 1090-1095 CrossRef PubMed
8. Chan, K., Han, X.D. and Kan, Y.W. (2001) An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl. Acad. Sci. U.S.A. 98, 4611-4616 CrossRef PubMed
9. Enomoto, A., Itoh, K., Nagayoshi, E., Haruta, J., Kimura, T., O'Connor, T., Harada, T. and Yamamoto, M. (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59, 169-177 CrossRef PubMed
10. Aleksunes, L.M., Goedken, M.J., Rockwell, C.E., Thomale, J., Manautou, J.E. and Klaassen, C.D. (2010) Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J. Pharmacol. Exp. Ther. 335, 2-12 CrossRef PubMed
11. Cho, H.Y., Reddy, S.P., Yamamoto, M. and Kleeberger, S.R. (2004) The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J. 18, 1258-1260 PubMed
12. Okawa, H., Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T.W. and Yamamoto, M. (2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun. 339, 79-88 CrossRef PubMed
13. Kim, H.J., Sato, T., Rodriguez-Iturbe, B. and Vaziri, N.D. (2011) Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J. Pharmacol. Exp. Ther. 337, 583-590 CrossRef PubMed
14. Kim, H.J. and Vaziri, N.D. (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am. J. Physiol. Renal Physiol. 298, F662-671 CrossRef PubMed
15. Aminzadeh, M.A., Nicholas, S.B., Norris, K.C. and Vaziri, N.D. (2013) Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol. Dial. Transplant. 28, 2038-2045 CrossRef PubMed
16. Copple, I.M. (2012) The Keap1-Nrf2 cell defense pathway-a promising therapeutic target? Adv. Pharmacol. 63, 43-79
17. Goldring, C.E., Kitteringham, N.R., Elsby, R., Randle, L.E., Clement, Y.N., Williams, D.P., McMahon, M., Hayes, J.D., Itoh, K., Yamamoto, M. and Park, B.K. (2004) Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice. Hepatology 39, 1267-1276 CrossRef PubMed
18. Copple, I.M., Goldring, C.E., Jenkins, R.E., Chia, A.J., Randle, L.E., Hayes, J.D., Kitteringham, N.R. and Park, B.K. (2008) The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology 48, 1292-1301 CrossRef PubMed
19. Fredriksson, L., Wink, S., Herpers, B., Benedetti, G., Hadi, M., de Bont, H., Groothuis, G., Luijten, M., Danen, E., de Graauw, M. et al. (2014) Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFalpha-mediated hepatotoxicity. Toxicol. Sci. 140, 144-159 CrossRef PubMed
20. Randle, L.E., Goldring, C.E., Benson, C.A., Metcalfe, P.N., Kitteringham, N.R., Park, B.K. and Williams, D.P. (2008) Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice. Toxicology 243, 249-260 CrossRef PubMed
21. Wilmes, A., Bielow, C., Ranninger, C., Bellwon, P., Aschauer, L., Limonciel, A., Chassaigne, H., Kristl, T., Aiche, S., Huber, C.G. et al. (2014) Mechanism of cisplatin proximal tubule toxicity revealed by integrating transcriptomics, proteomics, metabolomics and biokinetics. Toxicol., In Vitro, in the press
22. Wilmes, A., Crean, D., Aydin, S., Pfaller, W., Jennings, P. and Leonard, M.O. (2011) Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol. 25, 613-622, In Vitro
23. Wilmes, A., Limonciel, A., Aschauer, L., Moenks, K., Bielow, C., Leonard, M.O., Hamon, J., Carpi, D., Ruzek, S., Handler, A. et al. (2013) Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J. Proteomics 79, 180-194 CrossRef PubMed
24. Chen, P.C., Vargas, M.R., Pani, A.K., Smeyne, R.J., Johnson, D.A., Kan, Y.W. and Johnson, J.A. (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyte. Proc. Natl. Acad. Sci. U.S.A. 106, 2933-2938 CrossRef PubMed
25. Tobon-Velasco, J.C., Limon-Pacheco, J.H., Orozco-Ibarra, M., Macias-Silva, M., Vazquez-Victorio, G., Cuevas, E., Ali, S.F., Cuadrado, A., Pedraza-Chaverri, J. and Santamaria, A. (2013) 6-OHDA-induced apoptosis and mitochondrial dysfunction are mediated by early modulation of intracellular signals and interaction of Nrf2 and NF-kappaB factors. Toxicology 304, 109-119 CrossRef PubMed
26. Emter, R., Ellis, G. and Natsch, A. (2010) Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol. Appl. Pharmacol. 245, 281-290 CrossRef PubMed
27. Jennings, P., Limonciel, A., Felice, L. and Leonard, M.O. (2013) An overview of transcriptional regulation in response to toxicological insult. Arch. Toxicol. 87, 49-72 CrossRef PubMed
28. Wink, S., Hiemstra, S., Huppelschoten, S., Danen, E., Niemeijer, M., Hendriks, G., Vrieling, H., Herpers, B. and van de Water, B. (2014) Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment. Chem. Res. Toxicol. 27, 338-355 CrossRef PubMed
29. Krewski, D., Acosta, Jr, D., Andersen, M., Anderson, H., Bailar, J.C., 3rd, Boekelheide, K., Brent, R., Charnley, G., Cheung, V.G., Green, S., Jr. et al. (2010) Toxicity testing in the 21st century: a vision and a strategy. J. Toxicol. Environ. Health B Crit. Rev. 13, 51-138 CrossRef PubMed
30. Vinken, M. (2013) The adverse outcome pathway concept: a pragmatic tool in toxicology. Toxicology 312, 158-165 CrossRef PubMed
31. Kratschmar, D.V., Calabrese, D., Walsh, J., Lister, A., Birk, J., Appenzeller-Herzog, C., Moulin, P., Goldring, C.E. and Odermatt, A. (2012) Suppression of the Nrf2-dependent antioxidant response by glucocorticoids and 11beta-HSD1-mediated glucocorticoid activation in hepatic cells. PLoS One 7, e36774 CrossRef PubMed
32. Copple, I.M., Shelton, L.M., Walsh, J., Kratschmar, D.V., Lister, A., Odermatt, A., Goldring, C.E., Dinkova-Kostova, A.T., Honda, T. and Park, B.K. (2014) Chemical tuning enhances both potency toward nrf2 and in vitro therapeutic index of triterpenoids. Toxicol. Sci. 140, 462-469 CrossRef PubMed
33. Aschauer, L., Limonciel, A., Wilmes, A., Stanzel, S., Kopp-Schneider, A., Hewitt, P., Lukas, A., Leonard, M.O., Pfaller, W. and Jennings, P. (2014) Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: a transcriptomic study. Toxicol., In Vitro, in the press
34. Limonciel, A., Monks, K., Stanzel, S., Truisi, G.L., Parmentier, C., Aschauer, L., Wilmes, A., Richert, L., Hewitt, P., Mueller, S.O. et al. (2015) Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol., In Vitro, in the press
35. Elaut, G., Henkens, T., Papeleu, P., Snykers, S., Vinken, M., Vanhaecke, T. and Rogiers, V. (2006) Molecular mechanisms underlying the dedifferentiation process of isolated hepatocytes and their cultures. Curr. Drug Metab. 7, 629-660 CrossRef PubMed
36. Takayama, K., Morisaki, Y., Kuno, S., Nagamoto, Y., Harada, K., Furukawa, N., Ohtaka, M., Nishimura, K., Imagawa, K., Sakurai, F. et al. (2014) Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 111, 16772-16777 CrossRef PubMed
37. Oikawa, D., Akai, R., Tokuda, M. and Iwawaki, T. (2012) A transgenic mouse model for monitoring oxidative stress. Sci. Rep. 2, 229 CrossRef PubMed
38. Jaramillo, M.C. and Zhang, D.D. (2013) The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27, 2179-2191 CrossRef PubMed
39. Aleksunes, L.M., Goedken, M. and Manautou, J.E. (2006) Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury. World J. Gastroenterol. 12, 1937-1940 PubMed
40. Onderdijk, A.J., Balak, D.M., Baerveldt, E.M., Florencia, E.F., Kant, M., Laman, J.D., van, I.W. F., Racz, E., de Ridder, D., Thio, H.B. and Prens, E.P. (2014) Regulated genes in psoriatic skin during treatment with fumaric acid esters. Br. J. Dermatol. 171, 732-741 CrossRef PubMed
41. Hong, D.S., Kurzrock, R., Supko, J.G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J.P., Meyer, C.J., Ferguson, D.A. et al. (2012) A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 18, 3396-3406 CrossRef PubMed
42. Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S. and Yamamoto, M. (2000) Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 275, 16023-16029 CrossRef PubMed
43. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K. and Breckenridge, A.M. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329, 15-19 CrossRef PubMed
44. Kola, I. and Landis, J. (2004) Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3, 711-715 CrossRef
45. OECD (2015) Guidelines for the Testing of Chemicals, Test No. 442D: in Vitro Skin Sensitisation: ARE-Nrf2 Luciferase Test Method., Paris
46. Havrdova, E., Hutchinson, M., Kurukulasuriya, N.C., Raghupathi, K., Sweetser, M.T., Dawson, K.T. and Gold, R. (2013) Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012;367:1098-107;
47. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
48. Expert Opin. Pharmacother. 14, 2145-2156 CrossRef PubMed
49. Pergola, P.E., Raskin, P., Toto, R.D., Meyer, C.J., Huff, J.W., Grossman, E.B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H. et al. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 365, 327-336 CrossRef PubMed